Antibodies have transformed biopharma. Here, we look at the history of the modality and how new approaches are solving old problems.
Antibodies have transformed the treatment of many diseases and remain at the cutting edge of R&D. Yet, antibodies, like other modalities, continue to suffer from long development timelines and high rates of attrition. The key to tackling those problems lies at the very start of the drug development process, with decisions taken during the identification of the candidate panel and selection of the lead molecule reverberating throughout all of the subsequent steps.
In this white paper, we look at the past, present and future of antibodies as therapies, explaining how the modality became a key pillar of the biopharma industry—and looking forward to the methods and technologies that could unleash its full potential in the years to come. The paper covers:
The paper is essential reading for biopharma companies that want to build biologic pipelines and anyone interested in how antibodies transformed the industry.
Offered Free by: Charles River
See All Resources from: Charles River